Skip to content
Medical Health Aged Care

Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy

Fujirebio 2 mins read
  • Media:
GENT, Belgium--BUSINESS WIRE--

Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases.

“At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”

About Hepatitis C virus

Hepatitis C virus is one of the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (primary liver cancer), resulting in major global public health concerns. The HCV infection is unevenly distributed worldwide, with variations in prevalence across and within countries.1

Globally, an estimated 50 million people have chronic hepatitis C virus infection, with about 1.0 million new infections occurring per year. WHO estimated that in 2022, approximately 242 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma. Early detection and treatment can prevent serious liver damage and improve long-term health.2

About INNO-LiPA HCV 2.0 Genotyping

INNO-LiPA HCV 2.0 Genotyping products are IVDR-marked. The available* products are:

  • INNO-LiPA HCV 2.0 Genotyping <20T,CE> (Cat# 81547)
  • INNO-LiPA HCV 2.0 Amp <20T,CE> (Cat# 81548)
  • INNO-LiPA HCV 2.0 Control <3T,CE> (Cat# 81549)
  • LiRAS® for LiPA HCV v4 <CE> (Cat# 15228)

The assay is available in a size of 20T. The test can be performed manually or automated (on the TENDIGO™ (Cat# 80412) instrument) and is not intended to be used as a screening test for HCV or as a diagnostic test to confirm the presence of HCV.

Visit www.fujirebio.com for more information about this product.

* Please contact Fujirebio for further information about the local availability of the test.

References:

  1. Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, Razzack AA, Solimando AG, Thompson A, Andrews, K, Enebong Nya G, Ahmad S, Ranaldo R, Cozzolongo R, Shahini E. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg. 2021 Oct-Dec;84(4):637-656. doi: 10.51821/84.4.015. PMID: 34965046.
  2. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c


Contact details:

For media:
Public Relations Section, Public Relations/Sustainability Department,
H.U. Group Holdings, Inc..
Phone: +81-3-6279-0884
E-mail: pr@hugp.com

Christiaan De Wilde
CEO Fujirebio Europe
Phone: +32 9329 1703

For investors and analysts:
IR/SR Dept.
Phone: +81-3-5909-3337
E-mail: ir@hugp.com

Media

Images

3-1_01_FRlogo.jpg

Download media

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 19/03/2025
  • 10:23
Dementia Australia

‘Nostalgia’ ready to bloom – new show garden gives back to dementia

Award winning landscape designer Paul Pritchard will present his next show garden ‘Nostalgia’ created in support of Dementia Australia and in honour of his father who lived with Alzheimer's disease, at the upcoming Melbourne International Flower and Garden show. Following an extensive planning process, Mr Pritchard has designed a vibrant space with a nostalgic feel which aims to bring attention to dementia and its impact on the community. “I explored several concepts, but the final design took shape after the passing of my father to Alzheimer’s disease in May last year, making this garden especially meaningful to my family and…

  • Contains:
  • Federal Election, Medical Health Aged Care
  • 19/03/2025
  • 08:52
Royal Australian College of GPs

Over one million Australians deserve better access and lower costs for ADHD treatment

The Royal Australian College of GPs (RACGP) is calling for nationally uniform rules to ensure equitable access to attention deficit hyperactivity disorder (ADHD) treatment and medicines for the estimated one million plus Australians with ADHD during Neurodiversity Celebration Week. RACGP President Dr Michael Wright said: “ADHD is the most common neurodevelopmental condition in children and adolescents in Australia and while early diagnosis and treatment are crucial, many patients face long wait times and high costs for diagnosis and treatment. “Currently, different states have different rules for prescribing stimulant medications. “In some states, people can get treatment for ADHD from their…

  • Contains:
  • Medical Health Aged Care
  • 19/03/2025
  • 08:32
UNSW Sydney

‘Never too late’: quitting smoking after cancer diagnosis boosts survival rates, modelling shows

Australians who quit smoking after a cancer diagnosis could live years longer, new modelling shows, gaining precious time and boosting their quality of life. Those who quit smoking could live from a median of several months to more than two years longer than those who keep smoking, depending on their type of cancer and its severity, the research published in Cancer Epidemiology on Wednesday shows. “The earlier you stop smoking, the more beneficial it is, but it can still make a difference after a cancer diagnosis,” said senior author Associate Professor Freddy Sitas, from UNSW’s International Centre for Future Health…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.